Cansino Biologics Inc (688185) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.006x

Based on the latest financial reports, Cansino Biologics Inc (688185) has a cash flow conversion efficiency ratio of 0.006x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥30.53 Million ≈ $4.47 Million USD) by net assets (CN¥4.93 Billion ≈ $721.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cansino Biologics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Cansino Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 688185 current and long-term liabilities for a breakdown of total debt and financial obligations.

Cansino Biologics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cansino Biologics Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
BP PLC LSE:BP	0.103x
Zhe Jiang Kangsheng Co Ltd SHE:002418	-0.053x
Sinoseal Holding Co Ltd SHE:300470	0.038x
Henan Hengxing Science & Technology Co Ltd SHE:002132	0.017x
Shenzhen Anche Technologies Co Ltd SHE:300572	0.005x
Cymbria Corporation TO:CYB	0.002x
Shanghai Research Institute of Building Sciences Group Co. Ltd A SHG:603153	N/A
Shandong Fengyuan Chemical Co Ltd SHE:002805	0.004x

Annual Cash Flow Conversion Efficiency for Cansino Biologics Inc (2016–2024)

The table below shows the annual cash flow conversion efficiency of Cansino Biologics Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Cansino Biologics Inc.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥4.92 Billion ≈ $719.24 Million	CN¥-168.79 Million ≈ $-24.70 Million	-0.034x	+80.18%
2023-12-31	CN¥5.29 Billion ≈ $773.72 Million	CN¥-916.25 Million ≈ $-134.08 Million	-0.173x	+33.48%
2022-12-31	CN¥7.25 Billion ≈ $1.06 Billion	CN¥-1.89 Billion ≈ $-276.22 Million	-0.261x	-210.54%
2021-12-31	CN¥8.55 Billion ≈ $1.25 Billion	CN¥2.01 Billion ≈ $294.79 Million	0.236x	+404.82%
2020-12-31	CN¥6.07 Billion ≈ $888.36 Million	CN¥-469.39 Million ≈ $-68.69 Million	-0.077x	+33.19%
2019-12-31	CN¥1.47 Billion ≈ $215.18 Million	CN¥-170.19 Million ≈ $-24.90 Million	-0.116x	+52.98%
2018-12-31	CN¥502.32 Million ≈ $73.50 Million	CN¥-123.64 Million ≈ $-18.09 Million	-0.246x	-165.51%
2017-12-31	CN¥607.33 Million ≈ $88.87 Million	CN¥-56.30 Million ≈ $-8.24 Million	-0.093x	+42.17%
2016-12-31	CN¥214.47 Million ≈ $31.38 Million	CN¥-34.38 Million ≈ $-5.03 Million	-0.160x	--

About Cansino Biologics Inc

SHG:688185 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.03 Billion

CN¥7.04 Billion CNY

Market Cap Rank

#9007 Global

#2413 in China

Share Price

CN¥61.59

Change (1 day)

+0.13%

52-Week Range

CN¥55.60 - CN¥88.48

All Time High

CN¥773.75